Wednesday, July 8, 2026

Drug profile · INN

paramethadione

paramethadione (PARADIONE) is a voltage-gated t-type calcium channel blocker. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — paramethadione
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

paramethadione (PARADIONE) is a voltage-gated t-type calcium channel blocker. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN paramethadione
Brand PARADIONE
Mechanism Voltage-gated T-type calcium channel blocker
Target Voltage-gated T-type calcium channel
Route ORAL
Formulation CAPSULE

Mechanism of action

Voltage-gated T-type calcium channel blocker

Primary target: Voltage-gated T-type calcium channel

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. ethosuximide Voltage-gated T-type calcium channel blocker
  2. methsuximide Voltage-gated T-type calcium channel blocker
  3. phensuximide Voltage-gated T-type calcium channel blocker
  4. trimethadione Voltage-gated T-type calcium channel blocker

Frequently asked questions

What is paramethadione?

paramethadione (PARADIONE) is a voltage-gated t-type calcium channel blocker. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for paramethadione?

PARADIONE is a marketed brand name for paramethadione. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of paramethadione?

paramethadione has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.